Maren Keller

981 total citations
33 papers, 213 citations indexed

About

Maren Keller is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Maren Keller has authored 33 papers receiving a total of 213 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 12 papers in Oncology and 8 papers in Surgery. Recurrent topics in Maren Keller's work include Ovarian cancer diagnosis and treatment (15 papers), Renal cell carcinoma treatment (4 papers) and Cancer survivorship and care (4 papers). Maren Keller is often cited by papers focused on Ovarian cancer diagnosis and treatment (15 papers), Renal cell carcinoma treatment (4 papers) and Cancer survivorship and care (4 papers). Maren Keller collaborates with scholars based in Germany, Austria and Belgium. Maren Keller's co-authors include E. Mönch, M. Herrmann, H. Brösicke, H Helge, Jalid Sehouli, Rolf Richter, Hubert Serve, A Romański, K. Schwarz and Gesine Bug and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Maren Keller

30 papers receiving 206 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maren Keller Germany	9	68	59	52	51	46	33	213
G. Sabetta Italy	11	145 2.1×	43 0.7×	103 2.0×	25 0.5×	9 0.2×	29	279
Alina Sokup Poland	9	9 0.1×	12 0.2×	81 1.6×	23 0.5×	42 0.9×	20	263
MT Dattani United Kingdom	12	19 0.3×	25 0.4×	134 2.6×	6 0.1×	30 0.7×	14	387
J. Gillen United States	6	4 0.1×	19 0.3×	43 0.8×	25 0.5×	31 0.7×	17	158
Yuanhua Ye China	14	12 0.2×	9 0.2×	137 2.6×	21 0.4×	34 0.7×	34	446
Ron G. Rosenfeld United States	7	7 0.1×	46 0.8×	243 4.7×	29 0.6×	20 0.4×	8	522
Jürg Schwander Switzerland	9	12 0.2×	20 0.3×	118 2.3×	9 0.2×	45 1.0×	10	410
Ghada E. Esheba Egypt	9	3 0.0×	24 0.4×	73 1.4×	66 1.3×	54 1.2×	19	277
Alexander Mann Germany	6	14 0.2×	14 0.2×	80 1.5×	8 0.2×	12 0.3×	9	169
Nicola Poplawski Australia	10	14 0.2×	18 0.3×	73 1.4×	9 0.2×	34 0.7×	31	264

Countries citing papers authored by Maren Keller

Since Specialization

Citations

This map shows the geographic impact of Maren Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maren Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maren Keller more than expected).

Fields of papers citing papers by Maren Keller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maren Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maren Keller. The network helps show where Maren Keller may publish in the future.

Co-authorship network of co-authors of Maren Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Maren Keller. A scholar is included among the top collaborators of Maren Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maren Keller. Maren Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siegemund, T., et al.. (2025). Reduced half-life of recombinant ADAMTS13 in a patient with cTTP undergoing total hip arthroplasty. Thrombosis Journal. 23(1). 102–102.

Braicu, Elena Ioana, Klaus Pietzner, Purificación Estévez-García, et al.. (2023). First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).. Journal of Clinical Oncology. 41(16_suppl). TPS5620–TPS5620. 1 indexed citations

Runnebaum, Ingo B., J Jiménez Cruz, Anke Mothes, et al.. (2023). Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany. Journal of Cancer Research and Clinical Oncology. 149(10). 6953–6966. 10 indexed citations

Sehouli, Jalid, Alexander Mustea, Maren Keller, et al.. (2021). Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. Cancers. 13(19). 4739–4739. 4 indexed citations

Richter, Rolf, Sara Nasser, Radoslav Chekerov, et al.. (2021). Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany. BMC Cancer. 21(1). 1018–1018. 6 indexed citations

Faridi, Andreé, Stefan Paepke, Christine Mau, et al.. (2020). Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study. Breast Care. 16(5). 461–467. 4 indexed citations

Blohmer, Jens‐Uwe, Andreé Faridi, Stefan Paepke, et al.. (2020). Patient-Reported Outcomes and Aesthetic Results after Immediate Breast Reconstruction Using Human Acellular Dermal Matrices: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study. Breast Care. 16(4). 335–342. 3 indexed citations

Alavi, Sara, Rolf Richter, Maren Keller, et al.. (2020). Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). International Journal of Gynecological Cancer. 30(4). 509–514. 10 indexed citations

Armbrust, Robert, Peter Thuss‐Patience, Diana Lüftner, et al.. (2019). Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology. Archives of Gynecology and Obstetrics. 299(5). 1385–1389. 2 indexed citations

10.

Erdemoğlu, Evrim, Pesach Lichtenberg, Mustafa Zelal Muallem, et al.. (2019). A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer. Archives of Gynecology and Obstetrics. 300(1). 191–199. 16 indexed citations

11.

Ettl, Johannes, Jens‐Uwe Blohmer, Carsten Denkert, et al.. (2019). RESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer. Annals of Oncology. 30. iii25–iii25. 1 indexed citations

12.

Woopen, Hannah, Pauline Wimberger, Alexander Mustea, et al.. (2017). Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Annals of Oncology. 28. v340–v341. 3 indexed citations

13.

Sehouli, Jalid, Alexander Mustea, Jacek Grabowski, et al.. (2017). Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO). Annals of Oncology. 28. v341–v342. 2 indexed citations

14.

Salameh, Aida, Maren Keller, Ingo Dähnert, & Stefan Dhein. (2017). Olesoxime Inhibits Cardioplegia-Induced Ischemia/Reperfusion Injury. A Study in Langendorff-Perfused Rabbit Hearts. Frontiers in Physiology. 8. 324–324. 13 indexed citations

15.

Mustea, Alexander, Pauline Wimberger, Wolfgang Meinerz, et al.. (2016). Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group. Annals of Oncology. 27. vi299–vi299. 9 indexed citations

16.

Mustea, Alexander, Pauline Wimberger, Dietmar Reichert, et al.. (2015). 2754 First interim analysis of OTILIA, a large German non-interventional study evaluating front-line bevacizumab (BEV)-containing therapy in patients with ovarian cancer (OC). European Journal of Cancer. 51. S548–S548. 1 indexed citations

17.

Romański, A, K. Schwarz, Maren Keller, et al.. (2012). Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle. 11(17). 3219–3226. 24 indexed citations

18.

Schwarz, K., A Romański, Elena Puccetti, et al.. (2010). The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells. Leukemia Research. 35(1). 119–125. 14 indexed citations

19.

Mönch, E., et al.. (1996). Utilisation of amino acid mixtures in adolescents with phenylketonuria. European Journal of Pediatrics. 155(S1). S115–S120. 41 indexed citations

20.

Herrmann, M., H. Brösicke, Maren Keller, E. Mönch, & H Helge. (1994). Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. European Journal of Pediatrics. 153(7). 501–503. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact